Articles

Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi

Article Type

Corrigendum

Published

The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1

Read more

Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic

Tiago Torres, Marta Pereira, Maria João Paiva Lopes, Clarisse Rebelo, Pedro Andrade, Martinha Henrique, Hugo Oliveira, Paulo Ferreira, Gabriela Marques Pinto, Francisco Menezes Brandão, Jorge Rozeira, Paulo Filipe, Rui Tavares Bello

Article Type

Original Research

Published

This article describes the real-life strategies and therapeutic options adopted by dermatologists regarding their patients with psoriasis being treated with or with an indication for systemic therapy during the first COVID-19 lockdown period in Portugal.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.